United States - English - NLM (National Library of Medicine)

physicians total care, inc. - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg - enter section text here aciphex is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. aciphex is indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults and adolescents 12 years of age and above. aciphex is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. aciphex in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with

United States - English - NLM (National Library of Medicine)

lake erie medical & surgical supplies dba quality care products llc - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg

United States - English - NLM (National Library of Medicine)

carilion materials management - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg - aciphex delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd).  for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance).  controlled studies do not extend beyond 12 months. aciphex delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks.  aciphex delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers.  most patients heal within four weeks. aciphex delayed-release tablets, in combination with amoxicillin and clarithromycin as

United States - English - NLM (National Library of Medicine)

eisai inc. - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg - aciphex delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd).  for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance).  controlled studies do not extend beyond 12 months. aciphex delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks.  aciphex delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers.  most patients heal within four weeks. aciphex delayed-release tablets, in combination with amoxicillin and clarithromycin as

United States - English - NLM (National Library of Medicine)

avadel pharmaceuticals (usa), inc. - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 5 mg

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg

United States - English - NLM (National Library of Medicine)

cardinal health - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - rabeprazole sodium 20 mg

United States - English - NLM (National Library of Medicine)

direct_rx - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - 1.1 healing of erosive or ulcerative gerd in adults rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. 1.2 maintenance of healing of erosive or ulcerative gerd in adults rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. 1.3 treatment of symptomatic gerd in adults rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. 1.4 healing of duodenal ulcers in adults rabep

United States - English - NLM (National Library of Medicine)

woodward pharma services llc - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - aciphex delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. aciphex delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. aciphex delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. aciphex delayed-release tablets, in combination with amoxicillin and clarithromycin as a

United States - English - NLM (National Library of Medicine)

waylis therapeutics llc - rabeprazole sodium (unii: 3l36p16u4r) (rabeprazole - unii:32828355ll) - aciphex delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (gerd). for those patients who have not healed after 8 weeks of treatment, an additional 8-week course of aciphex may be considered. aciphex delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (gerd maintenance). controlled studies do not extend beyond 12 months. aciphex delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with gerd in adults for up to 4 weeks. aciphex delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. most patients heal within four weeks. aciphex delayed-release tablets, in combination with amoxicillin and clarithromycin as a